NAS began the study in 2010, and completed the first phase in 2012. The next phase had been underway for about three years when it was halted. The study was to have been an update to a 1990 review conducted by the National Cancer Institute, which analyzed cancer death rates in areas near 52 nuclear plants. That study concluded that there was no increased risk of cancer for people living close to the nuclear facilities.
The U.S. Department of Agriculture’s Food Safety and Inspection Service (FSIS) announced on Thursday that the recall is due to the products containing milk and soy, which are possible allergens, without providing that information on the product label.
Unlike most opioid painkillers, which are either taken on an empty stomach or without regard for food intake, users must take Xtampza after eating to release the maximum effects. The FDA warned that if Xtampza is taken without food, it will lead to inadequate pain control, and contribute to abuse and overdose by users who are seeking to remedy their pain.
The appeals ruling involved a class-action suit filed by relatives of alleged asbestos victims who accused BASF and Cahill of a systematic cover-up involving the destruction of key documents involving Engelhard asbestos litigation. Although the case in itself is not injury related, evidence of a cover-up could revive many previously litigated cases and cases in which plaintiffs settled for less than they would have had they attained access to factual information.
According to the FDA, Persons infected with the salmonella organism “often experience fever, diarrhea (which may be bloody), nausea, vomiting and abdominal pain” that in rare circumstances, “can result in the organism getting into the bloodstream and producing more severe illnesses such as arterial infections (i.e., infected aneurysms), endocarditis and arthritis.”
The U.S. Court of Appeals for the Federal Circuit granted a major victory for Novartis AG, the world’s pharmaceutical market leader. The court’s three-judge panel ruled 2-1 on Wednesday, declining a petition to renew a six-month injunction filed by competitor Amgen involving the marketing of a biosimilar drug comparable to Amgen’s breakthrough cancer treatment Neupogen
The terms of the agreement include Valeant paying AstraZeneca $100 million up front, adding another $170 million depending on pre-launch benchmarks, as well as up to $175 million depending upon sales benchmarks. After the product’s launch, the two companies will share profits. Valeant will handle the regulatory submission processes and the associated costs. In return, Valeant will retain the commercialization rights to brodalumab in all markets except in Japan and some Asian countries, where Amgen, the originator of the drug, had made a pre-existing agreement with Japanese biotech firm Kyowa Hakko Kirin.
Borders’s death is a stark reminder that many of those who endured the 9/11 tragedy are suffering from long-term health problems. Borders was asked if she thought that the debris from the terror attack, which contained glass and other carcinogenic dust, among other dangerous particles led to her cancer. She responded, “I’m saying to myself, ‘Did this thing ignite cancer cells in me?’ I definitely believe it because I haven’t had any illnesses. I don’t have high blood pressure, high cholesterol, diabetes.”
Judge Freda Wolfson of the U.S. District of New Jersey has granted some relief for drugmakers Bristol-Myers Squibb and Sanofi-Aventis in a complicated multidistrict whistleblower lawsuit against the two companies over marketing claims involving the blood-thinning medication Plavix. Wolfson granted motions to dismiss several claims made by former Sanofi sales representative Elisa Dickson, alleging that
The $3 billion industry has increasingly drawn the attention of both regulators. Among the questions the FDA brought up in the request for comment involve consumer and health provider attitudes towards homeopathic products, requests for data sources regarding the safety of the products, and what kind of measures could be implemented to improve the clarity of the CPG’s standard, among others.